clinical trial · NCT03901482
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc.·phase3·completed·n = 1,201
MigraineMigraine With AuraMigraine Without AuraDihydroergotaminePlacebos
brief summary
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine
started
Jun 24, 2019
primary completion
Jul 31, 2020
completion
Aug 13, 2020
last updated
Jun 29, 2023
detailed description
The EMERGE trial is a multi-center, single-dose, randomized, double-blind, placebo-controlled, parallel group study in subjects with acute migraine (ages 18 to 65 years).
official title
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol